The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Activated extracellular signal‐regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma
Open accessAbstract
BACKGROUND: Extracellular signal‐regulated kinase (ERK) promotes proliferation, metastasis, and poor survival in cancers of the breast, lung, and liver. Advanced localized renal cell carcinoma (RCC) is extraordinarily treatment resistant and has high recurrence rates despite surgery. Limited data exist regarding the prognostic significance of activated (phosphorylated) ERK in RCC. The authors hypothesized that activated ERK (pERK) promotes disease progression and metastasis in localized RCC and may be of value as a biomarker to predict disease recurrence. METHODS: The expression profile of pERK was examined by immunocytochemistry using a tissue microarray constructed from 174 drug treatment–naive patients who had undergone radical nephrectomy for localized RCC. Levels of tumor‐cell specific pERK were scored and correlated with clinicopathologic parameters of RCC and disease‐free survival. RESULTS: Immunostaining for pERK was present in 36% of all RCCs, with a predominance found in the clear cell histologic subtype. High expression was associated with increased tumor size, increased TNM stage, and vascular invasion. Patients with pERK‐positive tumors had a mean disease‐free survival of 4.19 years, compared with 6.38 years for patients with pERK‐negative tumors (P < .001). Cox regression models revealed pERK to be a significant independent predictor of disease‐free survival, with a hazards score of 2.9 (P < .001), a value similar to tumor grade (hazards ratio, 3.01; P < .001). CONCLUSIONS: Expression of pERK is an independent prognostic factor in RCC that is associated with advanced and aggressive pathologic features of renal tumors and predicts the onset of metastasis in patients with localized disease. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“constitutive activation of the ERK pathway is itself an independent factor associated with poor prognosis in RCC”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724
The Heidelberg classification of renal cell tumours
Kovács, G., Akhtar, M., Beckwith, B., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,353
Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W., & Charbonneau, C. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.001 · Cited by 974
Role of MAP kinase in tumor progression and invasion
Reddy, K. B., Nabha, S. M., & Atanaskova, N. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023781114568 · Cited by 517
Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
Gollob, J., Wilhelm, S. A., CARTER, C., & Kelley, S. K. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 368
Ebisuya, M., Kondoh, K., & Nishida, E. (2005) · Journal of Cell Science · doi:10.1242/jcs.02505 · Cited by 331
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.
Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., & Yoshida, O. (1995) · PubMed · Cited by 299
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
Faivre, S. J., Djelloul, S., & Raymond, É. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 274
RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE
FIGLIN, R. A. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61897-4 · Cited by 266
Elser, C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2871 · Cited by 252
Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., & Nicholson, R. I. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<247::aid-ijc1042>3.0.co;2-s · Cited by 251
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
Kim, H. L., Seligson, D. B., Liu, X., Janzen, N. K., BUI, M. H. T., Yu, H., Shi, T., Figlin, R. A., Horvath, S., & Belldegrun, A. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0488 · Cited by 233
USING TUMOR MARKERS TO PREDICT THE SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Kim, H. L., Seligson, D. B., Liu, X., Janzen, N. K., BUI, M. H. T., Yu, H., Shi, T., Belldegrun, A. S., Horvath, S., & Figlin, R. A. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000154351.37249.f0 · Cited by 216
LeFloch, R., Pouysségur, J., & Lenormand, P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-07 · Cited by 212
Huang, D., Ding, Y., Luo, W.-M., Bender, S., Qian, C., Kort, E. J., Zhang, Z., VandenBeldt, K. J., Duesbery, N. S., Resau, J. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5311 · Cited by 212
ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially
Vantaggiato, C., Formentini, I., Bondanza, A., Bonini, C., Naldini, L., & Brambilla, R. (2006) · Journal of Biology · doi:10.1186/jbiol38 · Cited by 210
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
Vicent, S., López-Picazo, J. M., Toledo, G., Lozano, M. D., Torre, W., Garcia-Corchón, C., Quero, C., Soria, J., Martín‐Algarra, S., Manzano, R. G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601644 · Cited by 186
Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation
Minet, E., Michel, G., Mottet, D., Raes, M. J., & Michiels, C. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00657-8 · Cited by 184
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Townsley, C. A., Major, P. P., Siu, L. L., Dancey, J. E., CHEN, E., Pond, G. R., Nicklee, T., Ho, J., Hedley, D. W., Tsao, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603055 · Cited by 179
Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Calvo, E., & Baselga, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5961 · Cited by 160
Targeted therapy for metastatic renal cell carcinoma
Patel, P. H., Chaganti, R. S. K., & Motzer, R. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602978 · Cited by 149
Ashcroft, G. S., Herrick, S. E., Tarnuzzer, R. W., Horan, M. A., Schultz, G. S., & Ferguson, M. W. J. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<169::aid-path915>3.0.co;2-q · Cited by 117
Milde‐Langosch, K., Bamberger, A., Rieck, G., Grund, D., Hemminger, G., Müller, V., & Löning, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602655 · Cited by 110
HIF‐1 and AP‐1 Cooperate to Increase Gene Expression in Hypoxia: Role of MAP Kinases
Michiels, C., Minet, E., Michel, G., Mottet, D., Piret, J., & Raes, M. J. (2001) · IUBMB Life · doi:10.1080/15216540252774766 · Cited by 108
Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience
Lam, J. S., Klatte, T., Patard, J., Goel, R. H., Guillé, F., Lobel, B., Abbou, C.-C. C., TAILLE, A. D. L., Tostain, J., Cindolo, L., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.01.106 · Cited by 100
Frémin, C., Ezan, F., Boisselier, P., Bessard, A., Pagès, G., Pouysségur, J., & Baffet, G. (2007) · Hepatology · doi:10.1002/hep.21551 · Cited by 99
Tanimura, S., Asato, K., Fujishiro, S., & Kohno, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00670-3 · Cited by 92
Protein Kinases as Drug Targets in Cancer
Arslan, M. A., Kütük, Ö., & Başağa, H. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778742479 · Cited by 92
Campbell, L., Gumbleton, M., & Griffiths, D. F. R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601359 · Cited by 88
Self-citationActivation of the extracellular signal regulated kinase (ERK) pathway in human melanoma
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S., Palmer, A. A., Zhang, X. D., Thompson, J. F., Bron, L. P., & Hersey, P. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.025957 · Cited by 85
Sroka, I. C., Nagle, R. B., & Bowden, G. T. (2007) · Neoplasia · doi:10.1593/neo.07193 · Cited by 74
Tan, X., Egami, H., Abé, M., Nozawa, F., Hirota, M., & Ogawa, M. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.025338 · Cited by 74
Mizumoto, Y., Kyo, S., Mori, N., Sakaguchi, J., Ohno, S., Maida, Y., Hashimoto, M., Takakura, M., & Inoue, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00445.x · Cited by 65
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies
Chowdhury, S., Larkin, J., & Gore, M. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.028 · Cited by 62
Griffiths, D. F. R., Verghese, A., Golash, A., Kynaston, H., Matthews, P. N., HART, A. J. L., & Court, J. B. (2002) · British Journal of Urology · doi:10.1046/j.1464-410x.2002.02661.x · Cited by 59
Self-citationO‐charoenrat, P., Wongkajornsilp, A., Rhys‐Evans, P. H., & Eccles, S. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20228 · Cited by 59
Campbell, L., Jasani, B., Edwards, K., Gumbleton, M., & Griffiths, D. F. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604243 · Cited by 57
Self-citationInamoto, T., Azuma, H., Sakamoto, T., Kiyama, S., Ubai, T., Kotake, Y., Watanabe, M., & Katsuoka, Y. (2007) · Cancer Investigation · doi:10.1080/07357900701522471 · Cited by 47
Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma
Carroll, V. A., & Ashcroft, M. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-06-4738 · Cited by 47
Molecular markers for predicting prognosis of renal cell carcinoma
Nogueira, M. A., & Kim, H. L. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.028 · Cited by 45
Osada, S., Kanematsu, M., Imai, H., Goshima, S., & Sugiyama, Y. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2005.05.015 · Cited by 42
Horiguchi, A., Sumitomo, M., Asakuma, J., Asano, T., Zheng, R., Asano, T., Nanus, D. M., & Hayakawa, M. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.06.040 · Cited by 41
Metastatic non‐clear cell renal cell carcinoma: current therapeutic options
Schrader, A. J., Olbert, P. J., Hegele, A., Varga, Z., & Hofmann, R. W. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07462.x · Cited by 40
Steiner, T., Knels, R., & Schubert, J. (2004) · European Urology · doi:10.1016/j.eururo.2004.06.003 · Cited by 40
Corgna, E., Betti, M., Gatta, G., Roila, F., & Mulder, P. H. M. D. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.04.007 · Cited by 38
Prognostic factors in renal cell cancer
Park, W., & Eisen, T. G. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06828.x · Cited by 35
Koga, T., Hashimoto, S., Sugio, K., Yoshino, I., Nakagawa, K., Yonemitsu, Y., Sugimachi, K., & Sueishi, K. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<209::aid-ijc1036>3.0.co;2-r · Cited by 34
Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma
Thomas, D., Verghese, A., Kynaston, H., & Griffiths, D. F. R. (2003) · Histopathology · doi:10.1046/j.1365-2559.2003.01721.x · Cited by 32
Self-citationEvolving role of novel targeted agents in renal cell carcinoma.
Hutson, T. E., & Figlin, R. A. (2007) · PubMed · Cited by 31
Integrated therapy of kidney cancer
Longo, R., D’Andrea, M. R., Sarmiento, R., Salerno, F., & Gasparini, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm244 · Cited by 31
Kidney cancer: Past, present, and future
Novick, A. C. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.006 · Cited by 24
Targeted therapies for kidney cancer in urologic practice
Haas, N. B., & Uzzo, R. G. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.05.009 · Cited by 14
Phosphorylation of ERK1/2 and Prognosis of Clear Cell Renal Cell Carcinoma
Lee, H. J., Kim, D., Kang, G. H., Kwak, C. H., Ku, J. H., & Moon, K. C. (2008) · Urology · doi:10.1016/j.urology.2008.08.472 · Cited by 14
The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
Unnithan, J., & Rini, B. I. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.149 · Cited by 6
Cited by
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer
Li, G., Ci, W., Karmakar, S., Chen, K., Dhar, R., Fan, Z., Guo, Z., Zhang, J., Ke, Y., Wang, L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.007 · Cited by 185
The potential role of leptin in tumor invasion and metastasis
Ray, A., & Cleary, M. P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.11.002 · Cited by 157
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
Horiguchi, A., Asano, T., Kuroda, K., Sato, A., Asakuma, J., Ito, K., Hayakawa, M., Sumitomo, M., & Asano, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605691 · Cited by 123
Maeda, Y., Kawano, Y., Wada, Y., Yatsuda, J., Motoshima, T., Murakami, Y., Kikuchi, K., Imamura, T., & Eto, M. (2015) · Oncology Reports · doi:10.3892/or.2015.3800 · Cited by 56
Campbell, L., Aljayyoussi, G., Gutteridge, R., Gumbleton, N., Griffiths, R., Gumbleton, S., Smith, M. W., Griffiths, D. F., & Gumbleton, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-255 · Cited by 36
Self-citation
Metadata
- Authors
- Campbell, L., Nuttall, R., Griffiths, D., & Gumbleton, M.
- Affiliations
- Cardiff University (GB)
- Corresponding author
- Gumbleton, Mark
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-06-12
- Volume
- 115
- Issue
- 15
- Pages
- 3457-3467
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2147716540
- Cited by
- 29
- References
- 57
- Citations by year
- 2026: 1 · 2023: 1 · 2021: 2 · 2018: 1 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- extracellular signal-regulated kinase, ERK1/2 phosphorylation, renal cell carcinoma, localized renal cell carcinoma, prognostic factors, disease-free survival, recurrence, metastasis, clear cell renal cell carcinoma, radical nephrectomy, vascular invasion, tumor grade, MAPK signaling
- MeSH terms
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Enzyme Activation, Female, Humans, Immunohistochemistry, Kidney Neoplasms, Male, Middle Aged, Prognosis, Biomarkers, Mitogen-Activated Protein Kinase 1, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
